DBV Technologies Stock Shows a 10.64% Increase at Opening
DBV Technologies surged by 10.64% this Friday morning, moving from €3.81 to €4.21. This sharp rise is part of a marked acceleration over several weeks, with the stock already up 36.03% in seven days and 57.09% over three months. Since January, the increase has exceeded 12%, while over twelve months, the rise reaches 377.3%, far outpacing the CAC 40, which is slightly down by 0.15% this morning.
Technically, the stock is now well above its reference moving averages. The position at €4.21 places it significantly beyond the 50-day average (€2.93), indicating a strong short-term momentum, and well above the 200-day average (€2.10), reflecting a marked progression since the beginning of the year. The Relative Strength Index (RSI) stands at 66, a territory generally associated with short-term overextension, while the Chaikin Money Flow remains positive at 0.12, indicating that buying flows continue to dominate the trades despite the rapid progression. This setup translates into a persistent accumulation of buyers, even though the stock approaches resistance levels where consolidation may occur.
Volatility and Market Sensitivity
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The analysis of Bollinger Bands places the price between €2.69 and €3.87, a range that the stock has significantly exceeded, signaling increased volatility beyond usual parameters. The MACD remains slightly positive (line at €0.21 versus signal at €0.15), with a histogram of 0.06, indicating a moderate but present bullish momentum. The monthly volatility of 23.94% reflects the significant movements recorded in recent weeks. With a beta of -0.38, the stock shows an inverse sensitivity to the market, allowing it to progress when the index slightly declines, as is the case this morning.
Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
Financement pouvant atteindre 306,9 millions de dollars via PIPE
Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
